Does the 1:1:1 Transfusion Ratio Mortality Benefit Hold True in Ultra-massive Transfusion? A Study From the Product (Patient Related Outcomes During Ultra-massive transfusion multi-Center Trial) Consortium
Courtney Meyer(Emory University), Jonathan Nguyen(Grady Health System), Jason D. Sciarretta, Marta Rowh(Emory University), Rachel L. Choron(Rutgers, The State University of New Jersey), Negar Nekooei(LAC+USC Medical Center), Kenji Inaba(University of Southern California), T. Moran(Emory University), Allison G. McNickle(University of Nevada, Las Vegas), Stephanie Ross(Carolinas Medical Center), Jonathan P. Meizoso(University of Miami), Steven Trinh, Ashwini Kumar, Zach Grady(Emory University), Van Christian Sanderfer, Jianhua Zhang(Hong Kong Baptist University), James W. Smith(Indiana University School of Medicine), Smith Rn(Emory University), D. M. Filiberto(University of Tennessee Health Science Center), C. E. Jones Sayyid(University of Tennessee Health Science Center), W. B. Risinger(University of Louisville Hospital), C. L. Jacovides(Temple University Hospital), Patrick Greiffenstein, E. D. Trausch(Temple University Hospital), Melike Harfouche(University of Maryland, Baltimore)
Cited by 4
Related Papers
Transfusion of Plasma, Platelets, and Red Blood Cells in a 1:1:1 vs a 1:1:2 Ratio and Mortality in Patients With Severe Trauma
|JAMA|2015|2.5k
Genome encode analyses reveal the basis of convergent evolution of fleshy fruit ripening
|Nature Plants|2018|409
Updated guidelines to reduce venous thromboembolism in trauma patients: A Western Trauma Association critical decisions algorithm
|The Journal of Trauma: Injury, Infection, and Critical Care|2020|269
Current management of hemorrhage from severe pelvic fractures
|The Journal of Trauma: Injury, Infection, and Critical Care|2016|259